5810-55-9

Usage

Uses

Used in Pharmaceutical Industry:
3-Acetamidopiperidine is used as a key intermediate in the synthesis of medicinal chemicals for its significant role in the production of inhibitor drugs. Its presence in the synthesis process contributes to the development of effective pharmaceuticals that can address various health conditions.
Used in Drug Synthesis:
3-Acetamidopiperidine is used as a building block in the creation of new drug molecules, allowing for the development of innovative treatments and therapies. Its chemical properties make it a valuable component in the pharmaceutical research and development process, leading to the discovery of novel compounds with potential therapeutic applications.

InChI:InChI=1/C7H14N2O/c1-6(10)9-7-3-2-4-8-5-7/h7-8H,2-5H2,1H3,(H,9,10)

Upstream product

• 5867-45-8 N-(pyridin-3-yl)acetamide 
• 129888-62-6 N-(1-tert-butoxycarbonyl-3-piperidyl)acetamide 
• 462-08-8 pyridin-3-ylamine 
• 129888-60-4 1-(tert-Butoxycarbonyl)-3-(methanesulfonyloxy)piperidine 
• 129888-61-5 3-Azido-1-(tert-butoxycarbonyl)piperidine 
• 85275-45-2 N-tert-butoxycarbonyl-3-piperidinol 
• 6859-99-0 3-hydroxypiperazine 

Downstream Products

• 307532-02-1 3-amino-1-benzylpiperidine dihydrochloride 
• 74045-92-4 N'-(1-benzyl-3-piperidinyl)-N-(2-chloroethyl)urea 
• 60407-35-4 1-phenylmethyl-3-aminopiperidine 
• 60169-74-6 3-(N-acetamino)-1-benzylpiperidine 

Relevant academic research and scientific papers

BICYCLIC COMPOUNDS AS INHIBITORS OF PD1/PD-L1 INTERACTION/ACTIVATION

The compounds of Formula I is described herein along with their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof. The compounds described herein, their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof are bicyclic compounds that are inhibitors of PD-1/PD-L1 interaction/activation.

2-SUBSTITUTED-ETHYNYLTHIAZOLE DERIVATIVES AND USES OF SAME

The present invention provides 2-substituted-ethynylthiazole derivatives of formula (I): wherein R1, R2 and X are as defined herein, or a pharmaceutically acceptable salt thereof; and pharmaceutical compositions and methods of using same.

Determination of the gauche effect of 3-acetamido- and 3-acetoxy-piperidine and -tetrahydropyran by 1H-n.m.r. spectroscopy

The A-values of the acetamido and the acetoxy group were determined by low-temperature 1H-n.m.r. spectroscopy.The limiting values for the relevant vicinal coupling constants of the newly prepared trans- (22) and cis-5-acetoxy-2-(1-hydroxy-1-methylethyl)tetrahydropyran (24) were obtained at room temperature.The attractive gauche effect of AcNH-3 and AcO-3 in piperidines, piperidinium trifluoroacetates, and tetrahydropyrans was investigated by 1H-n.m.r. spectroscopy both at low temperature (integrals) and at room temperature (band widths and coupling constants).The results obtained at low temperature are more reliable.The position of the conformational equilibrium of N-(3-piperidyl)acetamide (11), N-(1-methyl-3-piperidyl)acetamide (12), and N-(tetrahydropyran-3-yl)acetamide (17) depends strongly upon the nature of the solvent and, in apolar solvents, upon the concentration.

Synthesis of nitrosourea derivatives of pyridine and piperidine as potential anticancer agents.

Nitrosourea derivatives 18-22 which utilize either a piperidine or pyridine ring as a carrier group were synthesized and evaluated for anticancer activity. N'-(1-Benzyl-4-piperidinyl)-N-(2-chloroethyl)-N-nitosourea hydrogen maleate (19) exhibited good activity against intracranial L1210 leukemia as well as the mouse ependymoblastoma brain tumor system. Compound 19 exhibited comparable activity in the Lewis lung carcinoma system to N,N'-bis(2-chloroethyl)-N-nitrosourea. Replacement of the N-benzyl group in both the 3-piperidinyl- and 4-piperidinylnitrosoureas resulted in less active compounds in all tumor systems tested. The 3-pyridylnitrosourea 22 was inactive in the L-1210 leukemia system.